FTH

Faeth Therapeutics, Inc.

Price Chart

Latest Quote

$26.31

+3.12 (+13.45%)

Current Price

Previous Close	$23.19
Open	$23.30
Day High	$28.89
Day Low	$22.83
Volume	90,984

Fetched: 2026-06-23T17:29:20

Stock Information

Shares Outstanding	25.78M
Total Debt	$1.04M
Cash Equivalents	$202.79M
Net Income	$-184.46M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$678.24M
EPS (TTM)	$-142.72
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-170.63M
Income	$-184.46M
Book/sh	$-102.43
Cash/sh	$7.87
Employees	29

Financial Ratios

Quick Ratio	14.29
Current Ratio	14.39

Returns & Margins

ROA

-95.24%

Ownership

Insider Ownership	1.45%
Institutional Ownership	7.97%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

-0.26

Analyst Data

Recommendation	strong_buy
Target Price	$52.50

Technical Indicators

SMA20	$16.40
SMA50	$21.89
SMA200	$16.57
RSI	72.87
ATR	3.1086

Shares Float	812K
Short Float	84.60%
Short Ratio	23.85
Volatility	-0.23
Rel Volume	1.18

Performance History

Week	+89.96%
Month	+49.83%
Quarter	-19.74%
6 Months	+188.49%
YTD	+172.78%
Year	+243.47%
3 Years	-1.83%
5 Years	-89.41%
10 Years	-93.04%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-23	$26.31	90,984
2026-06-22	$23.19	102,200
2026-06-18	$17.82	65,900
2026-06-17	$16.65	166,900
2026-06-16	$14.53	155,500
2026-06-15	$13.85	219,700
2026-06-12	$13.00	58,000
2026-06-11	$10.79	71,100
2026-06-10	$11.41	52,000
2026-06-09	$12.63	55,600
2026-06-08	$13.00	49,500
2026-06-05	$14.65	50,800
2026-06-04	$16.60	36,800
2026-06-03	$15.85	44,500
2026-06-02	$16.09	60,500
2026-06-01	$19.79	66,900
2026-05-29	$21.14	70,000
2026-05-28	$17.59	40,500
2026-05-27	$16.65	53,500
2026-05-26	$16.47	27,200

About Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.

📰 Latest News

Frontier Transport Holdings (JSE:FTH) Will Pay A Dividend Of ZAR0.277

Simply Wall St. • 2025-12-10T04:00:31Z

Frontier Transport Holdings (JSE:FTH) Might Become A Compounding Machine

Simply Wall St. • 2025-12-08T11:42:12Z

Frontier Transport Holdings Limited's (JSE:FTH) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Simply Wall St. • 2025-10-22T06:36:29Z

Investors in Frontier Transport Holdings (JSE:FTH) have seen massive returns of 316% over the past five years

Simply Wall St. • 2025-07-23T11:44:57Z

Return Trends At Frontier Transport Holdings (JSE:FTH) Aren't Appealing

Simply Wall St. • 2025-06-26T10:32:07Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$32,000	$90,000	$144,000	$219,000
Total Expenses	$22,288,000	$31,663,000	$37,064,000	$50,188,000
Other Income Expense	$-4,000	$-954,000	$-517,000	$36,000
Other Non Operating Income Expenses	$-4,000	$-3,000	$-215,000	$36,000
Net Non Operating Interest Income Expense	$1,207,000	$2,460,000	$3,480,000	$1,564,000
Interest Expense Non Operating	$32,000	$90,000	$144,000	$219,000
Operating Expense	$22,288,000	$31,663,000	$37,064,000	$50,188,000
General And Administrative Expense	$11,328,000	$13,036,000	$18,765,000	$19,805,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-21,085,000	$-30,157,000	$-34,101,000	$-48,588,000
Net Interest Income	$1,207,000	$2,460,000	$3,480,000	$1,564,000
Interest Income	$1,239,000	$2,550,000	$3,624,000	$1,783,000
Normalized Income	$-21,085,000	$-29,206,000	$-33,799,000	$-48,588,000
Net Income From Continuing And Discontinued Operation	$-21,085,000	$-30,157,000	$-34,101,000	$-48,588,000
Total Operating Income As Reported	$-22,288,000	$-32,614,000	$-37,064,000	$-50,188,000
Net Income Common Stockholders	$-21,085,000	$-30,157,000	$-34,101,000	$-48,588,000
Net Income	$-21,085,000	$-30,157,000	$-34,101,000	$-48,588,000
Net Income Including Noncontrolling Interests	$-21,085,000	$-30,157,000	$-34,101,000	$-48,588,000
Net Income Continuous Operations	$-21,085,000	$-30,157,000	$-34,101,000	$-48,588,000
Pretax Income	$-21,085,000	$-30,157,000	$-34,101,000	$-48,588,000
Special Income Charges	$0	$-951,000	$-302,000	$0
Interest Income Non Operating	$1,239,000	$2,550,000	$3,624,000	$1,783,000
Operating Income	$-22,288,000	$-31,663,000	$-37,064,000	$-50,188,000
Per Share
Diluted EPS	$-16.72	$-24.00	$-24.40	$-31.60
Basic EPS	$-16.72	$-24.00	$-24.40	$-31.60
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-20,914,000	$-27,794,000	$-32,304,000	$-47,022,000
Total Unusual Items	$0	$-951,000	$-302,000	$0
Total Unusual Items Excluding Goodwill	$0	$-951,000	$-302,000	$0
Reconciled Depreciation	$139,000	$1,322,000	$1,351,000	$1,347,000
EBITDA (Bullshit earnings)	$-20,914,000	$-28,745,000	$-32,606,000	$-47,022,000
EBIT	$-21,053,000	$-30,067,000	$-33,957,000	$-48,369,000
Diluted Average Shares	$1,260,772	$1,255,861	$1,397,642	$1,535,164
Basic Average Shares	$1,260,772	$1,255,861	$1,397,642	$1,535,164
Diluted NI Availto Com Stockholders	$-21,085,000	$-30,157,000	$-34,101,000	$-48,588,000
Impairment Of Capital Assets	$0	$951,000	$0	-
Research And Development	$10,960,000	$18,627,000	$18,299,000	$30,383,000
Selling General And Administration	$11,328,000	$13,036,000	$18,765,000	$19,805,000
Other Gand A	$11,328,000	$13,036,000	$18,765,000	$19,805,000
Gain On Sale Of Ppe	-	$0	$-302,000	$0
Other Special Charges	-	-	-	-

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$18,592,000	$38,386,000	$64,895,000	$103,407,000
Total Assets	$22,902,000	$45,361,000	$74,374,000	$118,375,000
Total Non Current Assets	$1,395,000	$3,432,000	$7,124,000	$9,786,000
Other Non Current Assets	$18,000	$48,000	$86,000	$63,000
Current Assets	$21,507,000	$41,929,000	$67,250,000	$108,589,000
Other Current Assets	$92,000	$120,000	$325,000	$344,000
Prepaid Assets	$231,000	$474,000	$1,168,000	$1,129,000
Cash Cash Equivalents And Short Term Investments	$21,184,000	$41,335,000	$65,757,000	$107,116,000
Cash And Cash Equivalents	$8,668,000	$9,994,000	$13,011,000	$17,795,000
Current Deferred Assets	-	-	-	-
Debt
Total Debt	$1,509,000	$3,845,000	$6,208,000	$8,033,000
Long Term Debt And Capital Lease Obligation	$59,000	$1,527,000	$3,769,000	$5,902,000
Current Debt And Capital Lease Obligation	$1,450,000	$2,318,000	$2,439,000	$2,131,000
Liabilities
Total Liabilities Net Minority Interest	$4,310,000	$6,975,000	$9,479,000	$14,968,000
Total Non Current Liabilities Net Minority Interest	$59,000	$1,527,000	$3,836,000	$5,902,000
Current Liabilities	$4,251,000	$5,448,000	$5,643,000	$9,066,000
Other Current Liabilities	$77,000	$126,000	-	-
Payables And Accrued Expenses	$1,404,000	$1,122,000	$1,694,000	$4,473,000
Payables	$689,000	$244,000	-	-
Accounts Payable	$689,000	$244,000	-	-
Other Non Current Liabilities	-	-	$67,000	-
Equity
Common Stock Equity	$18,592,000	$38,386,000	$64,895,000	$103,407,000
Total Equity Gross Minority Interest	$18,592,000	$38,386,000	$64,895,000	$103,407,000
Stockholders Equity	$18,592,000	$38,386,000	$64,895,000	$103,407,000
Gains Losses Not Affecting Retained Earnings	$1,000	$-13,000	$-209,000	$-1,004,000
Other Equity Adjustments	$1,000	$-13,000	$-209,000	$-1,004,000
Retained Earnings	$-283,137,000	$-262,052,000	$-231,895,000	$-197,794,000
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$1,261,685	$1,259,029	$1,251,509	$1,538,208
Share Issued	$1,261,685	$1,259,029	$1,251,509	$1,538,208
Tangible Book Value	$18,592,000	$38,386,000	$64,895,000	$103,407,000
Invested Capital	$18,592,000	$38,386,000	$64,895,000	$103,407,000
Working Capital	$17,256,000	$36,481,000	$61,607,000	$99,523,000
Capital Lease Obligations	$1,509,000	$3,845,000	$6,208,000	$8,033,000
Total Capitalization	$18,592,000	$38,386,000	$64,895,000	$103,407,000
Additional Paid In Capital	$301,728,000	$300,451,000	$296,996,000	$302,202,000
Capital Stock	$0	$0	$3,000	$3,000
Common Stock	$0	$0	$3,000	$3,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$59,000	$1,527,000	$3,769,000	$5,902,000
Current Capital Lease Obligation	$1,450,000	$2,318,000	$2,439,000	$2,131,000
Pensionand Other Post Retirement Benefit Plans Current	$1,320,000	$1,882,000	$1,510,000	$2,462,000
Current Accrued Expenses	$715,000	$878,000	-	-
Net PPE	$1,377,000	$3,384,000	$7,038,000	$9,723,000
Accumulated Depreciation	$-540,000	$-1,496,000	$-1,727,000	$-1,443,000
Gross PPE	$1,917,000	$4,880,000	$8,765,000	$11,166,000
Leases	$253,000	$253,000	$253,000	$253,000
Other Properties	$1,295,000	$4,273,000	$7,980,000	$10,381,000
Machinery Furniture Equipment	$369,000	$354,000	$532,000	$532,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$12,516,000	$31,341,000	$52,746,000	$89,321,000
Treasury Shares Number	-	-	$0	-

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-20,469,000	$-24,816,000	$-32,203,000	$-39,347,000
Operating Activities
Operating Cash Flow	$-20,453,000	$-24,670,000	$-32,023,000	$-39,026,000
Cash Flow From Continuing Operating Activities	$-20,453,000	$-24,670,000	$-32,023,000	$-39,026,000
Operating Gains Losses	-	-	$302,000	$-30,000
Investing Activities
Capital Expenditure	$-16,000	$-146,000	$-180,000	$-321,000
Investing Cash Flow	$19,772,000	$22,440,000	$38,412,000	$49,949,000
Cash Flow From Continuing Investing Activities	$19,772,000	$22,440,000	$38,412,000	$49,949,000
Financing Activities
Repurchase Of Capital Stock	$-1,000	$0	$-10,384,000	$0
Financing Cash Flow	$-645,000	$-787,000	$-11,173,000	$-287,000
Cash Flow From Continuing Financing Activities	$-645,000	$-787,000	$-11,173,000	$-287,000
Net Other Financing Charges	$-3,000	$-10,000	$-76,000	-
Net Common Stock Issuance	$-1,000	$0	$-10,384,000	$0
Issuance Of Capital Stock	-	-	-	$0
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Common Stock Issuance	-	-	-	$0
Other
Repayment Of Debt	$-790,000	$-811,000	$-761,000	$-629,000
Issuance Of Debt	$142,000	$0	-	-
End Cash Position	$8,668,000	$9,994,000	$13,011,000	$17,795,000
Beginning Cash Position	$9,994,000	$13,011,000	$17,795,000	$7,159,000
Changes In Cash	$-1,326,000	$-3,017,000	$-4,784,000	$10,636,000
Proceeds From Stock Option Exercised	$7,000	$34,000	$48,000	$342,000
Common Stock Payments	$-1,000	$0	$-10,384,000	$0
Net Issuance Payments Of Debt	$-648,000	$-811,000	$-761,000	$-629,000
Net Long Term Debt Issuance	$-648,000	$-811,000	$-761,000	$-629,000
Long Term Debt Payments	$-790,000	$-811,000	$-761,000	$-629,000
Long Term Debt Issuance	$142,000	$0	-	-
Net Investment Purchase And Sale	$19,538,000	$22,586,000	$38,426,000	$50,255,000
Sale Of Investment	$44,693,000	$67,181,000	$59,575,000	$97,124,000
Purchase Of Investment	$-25,155,000	$-44,595,000	$-21,149,000	$-46,869,000
Net PPE Purchase And Sale	$234,000	$-146,000	$-14,000	$-306,000
Sale Of PPE	$250,000	$0	$166,000	$15,000
Purchase Of PPE	$-16,000	$-146,000	$-180,000	$-321,000
Change In Working Capital	$-1,592,000	$-489,000	$-4,330,000	$1,008,000
Change In Other Working Capital	$-562,000	$666,000	$-650,000	$709,000
Change In Other Current Liabilities	$-1,586,000	$-1,648,000	$-1,272,000	$-1,141,000
Change In Other Current Assets	$80,000	$244,000	$22,000	$5,000
Change In Payables And Accrued Expense	$233,000	$-445,000	$-2,331,000	$2,017,000
Change In Prepaid Assets	$243,000	$694,000	$-99,000	$-582,000
Other Non Cash Items	$1,510,000	$1,554,000	$1,357,000	$1,194,000
Stock Based Compensation	$1,274,000	$3,135,000	$4,454,000	$5,812,000
Asset Impairment Charge	$0	$951,000	$0	-
Amortization Of Securities	$-699,000	$-986,000	$-1,056,000	$231,000
Depreciation Amortization Depletion	$139,000	$1,322,000	$1,351,000	$1,347,000
Depreciation And Amortization	$139,000	$1,322,000	$1,351,000	$1,347,000
Depreciation	$139,000	$1,322,000	$1,351,000	$1,347,000
Net Income From Continuing Operations	$-21,085,000	$-30,157,000	$-34,101,000	$-48,588,000
Gain Loss On Sale Of PPE	-	$0	$302,000	$-15,000
Interest Paid Supplemental Data	-	-	-	$0
Gain Loss On Investment Securities	-	-	-	$-15,000
Net Business Purchase And Sale	-	-	-	-
Purchase Of Business	-	-	-	-
Change In Accrued Expense	-	-	-	-
Change In Interest Payable	-	-	-	-
Change In Payable	-	-	-	-
Change In Account Payable	-	-	-	-

Fetched: 2026-06-22